# Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

> **NCT00003497** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003497
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-08-21
- **Primary completion:** 1998-02-02
- **Final completion:** 1998-02-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003497, "Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00003497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*